DTC Ad Spending Fell In 2008 And Pharma Should Respond By Rebalancing Budgets
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug makers look to integrate promotional channels to increase ROI, while cutting back on ads
You may also be interested in...
Internet Searching May Get ‘Riskier’ For Patients After FDA Citations
“Sponsored searches” need to contain risk information, agency tells 14 firms in letters covering 48 products.
Big Pharma Still Hopeful For Next Mega Drugs To Supplement Sales
Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.
Affymax's Share Price Stumbles On Questionable Phase III Hematide Data
Phase III data for Affymax/Takeda's anemia drug for chronic kidney failure signals potential regulatory hurdles in non-dialysis use.